Teva announced 25 presentations examining new Phase 3 clinical data for TV-46000

Teva Pharmaceuticals, announced 25 presentations examining new Phase 3 clinical data, post hoc analyzes and open-label extension (OLE) studies for both TV-46000 / mdc-IRM (risperidone extended-release injectable suspension for subcutaneous use ) and AUSTEDO® (deutetrabenazine) tablets. Study findings will be presented at the upcoming 2021 Psych Congress Annual Meeting taking place Oct. 29-Nov. 1, 2021 in San Antonio, TX (in addition to virtual participation).
These data underscore Teva’s commitment to addressing the current unmet needs in managing mental illness. Combining creativity, scientific rigor and extensive knowledge on a broad range of technologies, Teva is working to not only uncover the full potential of existing medications, but to also provide new treatment options to support the management of neurological and psychiatric disorders like schizophrenia and tardive dyskinesia (TD).
 
"Those living with a serious mental illness face and overcome challenges every day, and we are committed to the advancement of science in mental health," said Matthias Mueller, MD MSc, VP Global Medical Affairs at Teva. "We continue to build upon our heritage in mental health through the development and delivery of medicines that help address the real-world challenges faced by this community of patients and providers."

Data presentations at this year’s Psych Congress evaluate the efficacy and safety profiles of investigational TV-46000, a subcutaneous risperidone injectable suspension being studied for the treatment of patients with schizophrenia. Presentations describe improvements in patient-centered outcomes, symptoms over time, as well as patient and healthcare professional choice and treatment experiences with TV-46000. Additional data that will be featured during the congress examine the physical, psychological and social impacts of TD on patients and caregivers, as well as explore the efficacy, safety and dosing patterns of long-term treatment with AUSTEDO® in patients with TD.